BB's Stock Haven

Reply Private New

Replies (1) Next 10 Prev Next

Send PM Follow Ignore

Followers	483
Posts	34748
Boards Moderated	0
Alias Born	01/14/2010

Nadendla

Re: None

Thursday, 07/18/2013 11:12:06 AM

Thursday, July 18, 2013 11:12:06 AM

SVFC ..HOT...RARE STOCK..CHECK THE DD..!!

The transfer agent for the company is Continental and the float is approximately 40M. There are 500M authorized shares and the outstanding shares is upwards of 150M with 39M in warrants.

CONTACT:

South Street Media, Inc.
(917) 937-8968

info@southstreetmedia.com

http://www.southstreetmedia.com/

If you have any investors or shareholders in SVFC that would like to either submit a question, or just be added to our SVFC investor mailing list, please register online below as this will help us organize a more professional corporate message going forward.
http://www.wallstreetnewscast.com/request/svfc.html

info@intellicellbiosciences.com
arhodes@intellicellbiosciences.com
Svictor@intellicellbiosciences.com
T: 646.576.8710
C: 917.209.6636
F: 212.249.1482

LATEST INTERVIEW OUT!!!..July 11, 2013

July 11, 2013 ..Interview with Dr. Victor, the Chairman and CEO of SVFC - July 11, 2013

http://www.wallstreetnewscast.com/profile/svfc.html

http://www.wallstreetnewscast.com/audio/svfc.wma

SVFC

INTELLICELL BIOSCIENCES Management has identified a number of acquisitions which could be negotiated that might be helpful to IntelliCell BioSciences in moving forward rapidly and solidifying its position as the technology leader in the Regenerative Medicine field in the United States and abroad
Amongst all the below listed Stem cell companies... They are the only public commercial stem cell company in the United States. IntellicellTM is the only company in the U.S. to meet FDA (Law 361) guidelines for this procedure!!.

Athersys, Inc. (ATHX) – $1.68 – Buy
Baxter (BAX) – $69.88 – NR
Capricor (private)
Cardio3 Biosciences (private)
Cytomedix (CMXI) – $0.42 – NR
Cytori Therapeutics (CYTX) – $2.43 – Buy
Dendreon (DNDN) – $4.48 – Sell
IntellicellBioScience (SVFC)-$0.05 - NR
Lonza (LONN.VX) – CHF72.30 -NR
Mesoblast Ltd. (MBLTY) – $25.14 – Buy
NeoStem, Inc. (NBS) – $0.57– NR
Osiris (OSIR) – $10.40 – NR
Pfizer (PFE) – $27.97 – NR
Pluristem (PSTI) – $2.98 – Hold
Teva Pharmaceuticals (TEVA) – $38.94 – Buy

Under the FDA’s Rule 361, IntelliCells is authorized to commercially sell its SVF stem cells in the U.S

...Intellicell Biosciences are in Discussions with MAJOR PHARMA's and Generic Pharmaceuticals about various Partnerships and Licensing Arrangements for many of INTELLICELLS key Products!!!...IN USA...and ABROAD!!...

..In addition to Millipore Corporation, which now has an agreement with IntelliCell BioSciences, management and its representatives have been in discussion with other major pharmas and generic pharmaceutical companies about various partnerships and licensing arrangements for many of IntelliCell’s key products, both in the United States and overseas.

http://www.cpreports.com/2011/11/20/market-alert-ray-dirks-research-report-on-intellicell-biosciences-svfc-november-21-2011/

On October 13,2011..This stock used to trade @$4.80 at its peak ....On March 15 2012...this traded @ $2.20 !!...At that time the company never had the latest patent that they have now...nor the FDA INDS applied for ..one of which will be out anytime..

https://www.google.com/finance?chdnp=1&chdd=1&chds=1&chdv=1&chvs=maximized&chdeh=0&chfdeh=0&chdet=1371347018608&chddm=448477&chls=IntervalBasedLine&q=OTCMKTS:SVFC&ntsp=0&ei=Pxi9UeDIB-mp0AHYvAE
New Approved Powerful Patent..Which can be a Game Changer..

http://ih.advfn.com/p.php?pid=nmona&article=57985645

http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=8,440,440.PN.&OS=PN/8,440,440&RS=PN/8,440,440

United States Patent 8,440,440
Victor May 14, 2013
Ultrasonic cavitation derived stromal or mesenchymal vascular extracts and cells derived therefrom obtained from adipose tissue and use thereof

Abstract
Methods of treating using adipose tissue using ultrasonic cavitation to dissociate the fat cells and blood vessels contained within adipose tissue and thereby obtain mesenchymal or stromal vascular fractions for use in human subjects are provided. These methods preferably do not include the use of any exogenous dissociating enzymes such as collagenase and result in increased numbers of the cells which constitute the mesenchymal or stromal vascular fractions (about 10-fold greater) than methods which use collagenase to isolate these cells.

Inventors: Victor; Steven (New York, NY)
Applicant:
Name City State Country Type

Victor; Steven
New York
NY
US
Assignee: Intellicell Biosciences Inc. (New York, NY)
Family ID: 46317059
Appl. No.: 13/323,030
Filed: December 12, 2011

REGENERATIVE...MEDICINE!..10 times more efficient than CYTORI(CYT*)..

Stem cells..Making more from less..especially from Fats..painless..no side effects..FAST..and MERCK is in DEEP.. n..:)

Veteran Wall Street analyst Ray Dirks said Intellicell's SVF cell therapy was a thousand times more potent than the current therapy of cortisone for treating inflammation, but it also re-grows tissue, cartilage, and blood vessels...

http://www.proactiveinvestors.com/companies/news/26420/cpreportscom-says-intellicells-therapy-a-game-changer-26420.html

Intellicells technology produces 10 times more number of SVF cells containing adult adipose stem cells from less than any of its present competition ..including CYTORI(CY*X)...

http://www.forbes.com/sites/genemarcial/2011/08/28/human-bodys-fat-seen-as-best-source-of-stem-cells-for-regenerative-therapies/

Intellicell Biosciences is compared to CYTORI on seekingalpha.com..Only Intellicell biosciences seems to have a far better tech as below..

http://seekingalpha.com/article/1276811-the-stem-cell-revolution-can-jump-start-your-portfolio-jason-kolbert

SVFC

IntelliCell's Chairman and CEO, Dr. Steven Victor, stated "Our Company is very pleased to announce today that with the publishing of our patent, our technology is now protected and we expect our international patent publication in a short time."

With this new approved Patent ..International Patent will be out too shortly..the company has plans to go GLOBAL!.
http://www.princetonresearch.com/Intellicell-3-2012.pdf

..So..The International patent will be approved in a short time..

...and the preclinical protocols in anticipation of beginning a clinical trial for osteoarthritis of the knee under an FDA investigational new drug application in mid-2013 ..which is now..the FDA approval news will hit anytime...

http://seekingalpha.com/article/1276811-the-stem-cell-revolution-can-jump-start-your-portfolio-jason-kolbert

The company also intends to explore combination therapies with patent pending bio-engineered products under development....he Company believes that the IntelliCell product is an efficient cellular delivery platform for a variety of therapeutic applications and will look to partner with technology developers...

...clearly means that there are more patents applied for and which are pending...

http://www.stemcellcafe.com/regenerative-medicine/intellicell-biosciences-announces-collaborative-agreement-with-the-university-of-florida-on-stem-cell-and-tissue.php

After a recent capital raising, the company has projected to have $1.5 million of cash and no debt.

http://www.proactiveinvestors.com/companies/news/26420/cpreportscom-says-intellicells-therapy-a-game-changer-26420.html

Revenues are already flowing through licensing..@ a million Dollars per licensing ..amazing revenue stream..their patents/technology can be licensed to other parties for a fee..each licensing earns them about a million dollars..the 2 licensing deals as under..

www.sec.gov/Archives/edgar/data/1125280/000101376212000880/form10k.htm

In consideration for the grant of the exclusive license, the licensee agreed to pay us an up-front license fee of $1,000,000 payable as follows: (i) an initial installment of One Hundred Fifty Thousand Dollars ($150,000) upon execution of the agreement; (ii) One Hundred Thousand Dollars ($100,000) within three (3) days of the completion of the Lab Equipment (as defined in the agreement) having been delivered and installed (in accordance with applicable cGMP’s and cGTP’s of the US FDA) and the Lab Technician (as defined in the agreement) for the initial Laboratory Facility (as defined in the Thailand Agreement) having completed training; and (iii) the balance of Seven Hundred Fifty Thousand Dollars ($750,000) to be placed in escrow with counsel for the Company upon the payment of the second installment, with such funds to be held in escrow for a period of ninety (90) days, with such funds to be released upon satisfaction by the parties that the Lab Equipment is in working order and the Lab Technician has been adequately trained.

The other recently concluded licensing agreement in Australia..

Intellicell Biosciences announces the licensing of its proprietary patent, pending stromal vascular fraction manufacturing technology!!..Intellicell has licensed its proprietary, patent, pending technology for the manufacture of stromal vascular fraction from adipose tissue to Cell-Innovations, Pty Limited a company headquartered in Sydney, Australia. The license calls for a one-time payment of $700,000 and a royalty stream of 12 ½ % of net of sales!!..and this is just one of many ..Just the beginning..

Thursday, June 20, 2013

www.wnd.com/markets/news/read/20356239/intellicell_biosciences_announces_the_licensing_of_its_proprietary_patent

Intellicell Biosciences, Inc. (OTCQB: SVFC) (PINKSHEETS: SVFC); (“Intellicell”) or the (“Company”), Intellicell has licensed its proprietary, patent, pending technology for the manufacture of stromal vascular fraction from adipose tissue to Cell-Innovations, Pty Limited a company headquartered in Sydney, Australia. The license calls for a one-time payment of $700,000 and a royalty stream of 12 ½ % of net of sales.

Intellicell’s process is a patent-pending non-enzymatic method for deriving stromal vascular fraction from 60cc’s of adipose tissue. This process dramatically increases the yield in manufacturing stromal vascular fraction compared to the present enzymatic methods in use today. Intellicell’s process generates between half billion - 1.4 billion SVFC cells from 60 ccs from a patient’s own adipose tissue. This is approximately 10-20 times greater than enzyme based methods. Dr. Steven Victor, CEO, said “we are extremely excited about our licensing partnership with Cell-Innovations, Inc. We believe they are one of the best positioned companies to market the Intellicell technology in Australia & New Zealand.

Cell-Innovations is an Australian company headquartered in Sydney servicing the burgeoning regenerative medicine market by providing innovative IntelliCell technology to the Australian and New Zealand marketplace. We believe that IntelliCell technology will be a “game-changer” in the regenerative medicine field making available stromal vascular fraction (SVF) treatment to the public. Cell-Innovations CEO is Dr. Wayne Thomas BSc PhD a founder of Australian Cell Technologies, a company introducing regenerative cellular products to the veterinary market. Dr. Thomas has 25 years experience in cell biology and developed kits for adipose SVF for the veterinary market. Dr. Thomas’ research contributions has been recognized by many publications and book chapters, and is a reviewer for both national and international granting bodies and journals; and, will be a scientific advisor for IntelliCell. Dr Ralph Bright MB ChB FFMACC is a director with Cell-Innovations and is a pioneer in stromal vascular fraction treatments in Australia, a Fellow and Member of many cosmetic medicine organizations including the Cosmetic Physicians Society of Australasia and the Australian College of Cosmetic Surgery. Dr Bright has been treating patients with adipose SVF since 2009 for osteoarthritis and degenerative neurological disease and is one of the most experienced physicians in Australia in the use of adipose SVF. “Cell-Innovations and IntelliCell will assist Macquarie Stem Cells to establish ‘Intellicell Centers of Excellence’ where doctors can treat their patient”

...with Revenues of 2 million dollars out of just 2 Licensing deals..the company makes close to 2 million dollars..imagine 50 deals ..world wide..or a hundred..it would be insane Revenue Generation..and the PPS will reflect the same ....

Private clinical labs will be sold around the country to physicians for an initial investment ($100-150,000) and the facility must be FDA compliant.

40 clinical lab centers are anticipated to be in major cities across the U.S. in the next 6-12 months and over 100 within 24 months, with trained FDA certified physicians; Each clinical lab is expected to generate over $100,000 per year in profits.

http://www.princetonresearch.com/Intellicell-3-2012.pdf

MERCK subsidiary Millipore collaborating with Intellicell Biosciences..Millipore(American Subsidiary of MERCK)has executed an exclusive supply and sale agreement with IntelliCell BioSciences to sell and distribute the guava flow cytometry platform into the area of SVF..

http://www.cpreports.com/2011/11/20/market-alert-ray-dirks-research-report-on-intellicell-biosciences-svfc-november-21-2011/

Here is Wilson Tawe, PhD, MBA Manager - Instrument FAS (North America) @ EMD Millipore(American Subsidiary of MERCK) sitting on the Board of Advisors..

http://www.intellicellbiosciences.com/corporate-profile.html

Medical Board of Advisors

Dr. James Andrews, The Andrews Institute
Dr. Harold Bafitis, The Plastic Surgery Institute of The Palm Beaches
Dr. Peter Bruno, Internist, New York City
Dr. Greg Cavaliere, Orthopedic Surgeon, NY Rangers
Dr. Gil Chimes DC, DICBN, CCSP, CSCS Greenwich Sports Medicine in Greenwich, CT
Dr. Sydney Coleman, Tribeca Plastic Surgery, New York City
Dr. Mathew Cooper Aventura Chiropractor, Aventura, FL
Dr. Alberto Goldman, Plastic Surgeon, Brazil
Dr. Joshua Hackel, The Andrews Institute
Dr. Anthony V. Maddalo, Orthopedic Surgeon, NY Rangers
Dr. Frederick Nicola, D.I.S.C. Sports & Spine Center, Marian del Rey, Oakland/LA Raiders
Dr. Eric Richter, Neurologist, Chief LSU Health Sciences Center
Wilson Tawe, PhD, MBA Manager - Instrument FAS (North America) @ EMD Millipore
Dr. Nicholas Toscano, Periodontist, Editor in Chief JIAD
Mr. Kevin Wilk, PT, DPT The Andrews Institute

EMD Millipore is a division of Merck KGaA, Darmstadt, Germany

http://www.millipore.com/company/flx4/about

https://lists.purdue.edu/pipermail/cytometry/2012-February/042840.html

Headquartered in Billerica, Massachusetts, EMD Millipore has some 10,000 employees in 67 countries motivated by the potential of science for life through a portfolio of more than 40,000 products. Comprised of three business units—Bioscience, Lab Solutions, and Process Solutions— EMD Millipore is a top tier supplier to the life science industry, and serves as a strategic partner for scientists, engineers, and researchers. For more information on the EMD Millipore portfolio, vision and mission, as well as careers, events and current news, refer to our divisional section.

EMD Millipore Headquarters
290 Concord Road
Billerica, MA 01821
978.715.4321
The EMD Group

EMD Millipore is part of the The EMD Group, a global pharmaceutical and chemical company which generated total revenues of EUR 9.3 billion in 2010 and has 40,000 dedicated employees worldwide. In North America, Merck, Darmstadt, Germany operates under the umbrella brand EMD (EMD Millipore), formed from the initials of Emanuel Merck, Darmstadt.

Intellicell Biosciences are the only public commercial stem cell company in the United States. IntellicellTM is the only company in the U.S. to meet FDA (Law 361) guidelines for this procedure!!.

http://www.princetonresearch.com/biosciences-news-intellicell-biosciences-inc-symbol-svfc-investment-research-report-issued/

Veteran Wall Street analyst Ray Dirks said Intellicell's SVF cell therapy was a thousand times more potent than the current therapy of cortisone for treating inflammation, but it also re-grows tissue, cartilage, and blood vessels...

Intellicells technology produces 10 times more number of SVF cells containing adult adipose stem cells from less than any of its present competition ..including CYTORI(CY*X)...

http://www.forbes.com/sites/genemarcial/2011/08/28/human-bodys-fat-seen-as-best-source-of-stem-cells-for-regenerative-therapies/

A study of IntelliCell’s technology by Millipore, a division of Merck AG of Germany, confirmed that it produced an average of 10 times the number of SVF cells containing adult adipose stem cells from less than which the company believes is used by any of its present competition that use enzymes in their process. The study also showed that the SVF cells produced by IntelliCell contain all of the viable cells that are manufactured by competing technologies that use enzymes, such as Cytori.

Under the FDA’s Rule 361, IntelliCells is authorized to commercially sell its SVF stem cells in the U.S

http://www.forbes.com/sites/genemarcial/2011/08/28/human-bodys-fat-seen-as-best-source-of-stem-cells-for-regenerative-therapies/

They are the only public commercial stem cell company in the United States. IntellicellTM is the only company in the U.S. to meet FDA (Law 361) guidelines for this procedure!!.

http://www.princetonresearch.com/biosciences-news-intellicell-biosciences-inc-symbol-svfc-investment-research-report-issued/

The Company is a pioneering regenerative medicine company focused on the expanding regenerative medical markets using stromal vascular fraction derived from adult adipose tissue. IntelliCell intends to initially focus on selling laboratory suites and licensing its technology to doctors for use in their offices for their patients.

The company is also setting up Centers of Excellence where doctors can treat their patients. In addition, IntelliCell BioScience in exploring storing the stromal vascular fraction in cryostorage for future uses. The company is also starting FDA IND clinical trials at major medical centers for clinical indication approval.

IntelliCell intends to pursue expansion to secondary markets and beyond the U.S. through a combination of company-owned and licensed clinical facilities.

SVFC

IntelliCell BioSciences wins key listing from FDA

http://www.medreps.com/biotechnology-company-news/intellicell-biosciences-wins-key-listing-from-fda/

Nov 09, 2012

In today's challenging healthcare sales market, biotechnology companies face many hurdles when trying to commercialize their products. Now, New York-based IntelliCell BioSciences has announced it has cleared a key roadblock to process its regenerative medicine technology.

The company said it has been notified by the Food and Drug Administration (FDA) that its facility in New York is now registered to recover, process package, store and label human cells and tissues for future development.

"The IntelliCell processing technology is designed to allow physicians to treat their patients during a same day and same procedure basis much the same way that bone marrow transplants and IVF treatments are performed today," Dr. Steven Victor, IntelliCell's chairman and chief executive officer, stated. "This is a significant step for the Company as it continues its mission to be a leading regenerative medicine company."

Although it's unclear whether the facility registration will allow the company to add more biotech sales jobs, it did say it was moving forward with plans for in-human clinical studies, including one for lower limb ischemia, which is a vascular disease that affects the arteries supplying blood to the legs. According to the National Institutes of Health, the condition often leads to amputation.

OneMedRadio: Intellicell BioSciences CEO Talks Stromal Vascular Cells...Intellicell has demonstrated the process is faster (about 30 minutes vs. 2 hours), less expensive, and more efficient than protocols using endotoxins and enzymes...IntelliCell will also be seeking to develop technology licensing agreements with technology developers, universities, and international business entities...Intellicell is now exploring clinical studies in autologous cellular treatments for osteoarthritis, periodontal (gingival gum regeneration), aesthetics (wrinkle market), sports medicine injuries, and multiple sclerosis.

http://www.onemedplace.com/blog/archives/12409

Intellicell Biosciences announces the licensing of its proprietary patent, pending stromal vascular fraction manufacturing technology!!..Intellicell has licensed its proprietary, patent, pending technology for the manufacture of stromal vascular fraction from adipose tissue to Cell-Innovations, Pty Limited a company headquartered in Sydney, Australia. The license calls for a one-time payment of $700,000 and a royalty stream of 12 ½ % of net of sales!!..and this is just one of many ..Just the beginning..

Thursday, June 20, 2013

http://www.wnd.com/markets/news/read/20356239/intellicell_biosciences_announces_the_licensing_of_its_proprietary_patent

IntelliCell plans to collaborate with International Partners to achieve optimal market entry opportunities and revenues.

http://www.cpreports.com/2011/11/20/market-alert-ray-dirks-research-report-on-intellicell-biosciences-svfc-november-21-2011/

..Millipore(MERCK) is already in...whose next...

Intellicell Biosciences is compared to CYTORI on seekingalpha.com..Only Intellicell biosciences seems to have a far better tech as below..

http://seekingalpha.com/article/1276811-the-stem-cell-revolution-can-jump-start-your-portfolio-jason-kolbert

The IntelliCell process, branded IntelliSonics, is similar to the Cytori process in that they both use lipoaspirate. But the IntelliCell process produces a different cellular population because, with its sonification [ultrasound] process, the blood components are not washed out[/color]. The stromal vascular fraction of IntelliCell contains the hematopoietic cells. The final product is quality-controlled, checked for any contamination and cell viability is measured.

IntelliCell BioSciences has completed the preclinical protocols in anticipation of beginning a clinical trial for osteoarthritis of the knee under an FDA investigational new drug application in mid-2013. The company provides product today to ReGen Medical, and in doing so is building fantastic database of patient experience that will be used to focus on clinical applications.

Dr. Steven Victor, is also the founder of ReGen Medical. ReGen Medical is a state-of-the-art hospital in midtown Manhattan that provides stromal vascular fraction cellular therapy, which contains stem cells, to patients today. The hospital is a beautiful, brand-new facility that treats high-end patients.

The future of medicine will reach an exciting stage when SVF will be stored in all major hospitals, similar to blood for transfusions, and these cells will be readily available to treat patients for a multitude of injuries and ailments (ie. orthopaedic, post myocardial infarction etc.)

http://www.prnewswire.com/news-releases/intellicell-biosciences-files-patent-application-for-a-new-research-technique-163399216.html

IntelliCell Announces Research Tissue Bank License..

http://www.prnewswire.com/news-releases/intellicell-announces-research-tissue-bank-license-172643221.html

IntelliCell BioScience Inc. Procedure Enables Norwegian Star Basketball Player to Fully Recover from Patella Tendinitis to Play for Manhattan College....

http://www.businesswire.com/news/home/20120221006314/en/IntelliCell-BioScience-Procedure-Enables-Norwegian-Star-Basketball

The next move would be applying that new patent to the following..

IntelliCell also plans to partner with other technology developers in the industry to examine the use of Vascular Fraction Cells in a number of clinically relevant areas such as:

Hair Loss in Men and Women

Rheumatoid Arthritis

Multiple Sclerosis

ALS Disease

Autism

Tinnitus

Bone fractures

Osteoarthritis

Sports Medicine Injuries

Gingival Gum Regeneration

Dermal treatment for burns and non-healing wounds

Intellicell Bioscience's Stromal Vascular Fraction Stem Cell Therapy to treat non-healing diabetic foot ulcers...

http://www.complexwoundhealing.org/research/stromal-vascular-fraction-stem-cell-therapy-for-diabetic-foot-ulcers.html

The Winthrop Wound Healing Center is currently investigating a promising new regenerative medicine approach that uses the patient’s own stromal vascular fraction (SVF) cells—a blood component rich in adult stem cells, which can help stimulate the regeneration of healthy tissue. The SVF cells we will be using are obtained from blood vessels in the patient’s adipose (fat) tissue through a process that uses high-frequency ultrasound to break up the fat tissue, then separates out the SVF cells using a centrifuge.

Our wound center is currently working on plans to launch a clinical trial that will evaulate the benefits of using SVF cells to treat non-healing diabetic foot ulcers. In the trial, which will utilize SVF cells supplied by IntelliCell Biosciences, the stem-cell therapy will be administered to patients through a combination of intravenous infusion and topical injection into the wound site. The healing of DFUs and other chronic wounds is just one potential application for SVC-stem cell therapy: It is also being investigated as a possible treatment for osteoarthritis, gum cavity degeneration and multiple sclerosis.

INTELLICELL BIOSCIENCES ANNOUNCES CLINICAL STUDY FOR DIABETIC CRITICAL LIMB ISCHEMIA...

http://www.ascrnetwork.com/index.php?option=com_content&view=article&id=2972%3Aintellicell-biosciences-announces-clinical-study-for-diabetic-critical-limb-ischemia&catid=101

NEW YORK, Sept. 13, 2012 /PRNewswire/ -- IntelliCell BioSciences, Inc. ("Company") (OTCQB: SVFC) announced today that it will be initiating a groundbreaking in-human clinical study to treat people who suffer from diabetic induced critical limb ischemia wounds. IntelliCell has developed a proprietary treatment methodology using its autologous (your own) cellular therapy that includes adult stem cells that have demonstrated regenerative capabilities in anecdotal studies of patients treated. According to the American Diabetes Association, there are "over 65,000 lower limb amputations performed in the United States" as a direct consequence of diabetes and hundreds of thousands of diabetes related amputations globally.
Dr. Steven Victor, Chairman and CEO of IntelliCell stated, "Diabetes is a growing problem in the United States and around the world. We hope to show that our unique autologous cellular therapy may make a contribution to those who suffer from this terrible disease and reduce the number of people that undergo amputations from non-healing wounds in their legs and other extremities."

Robert Sexauer, VP of Clinical Development added, "Regenerative Medicine is progressing to the point whereby we can begin to truly offer personalized medicine based on each patients unique needs. IntelliCell has developed a novel treatment methodology that may impact a number of disease states with significant unmet clinical needs."

IntelliCell™ Can Treat Joint Pain Without Painful Surgery

http://www.princetonresearch.com/Intellicell-3-2012.pdf

IntelliCell™ BioSciences, Inc. (SVFC.PK) developed proprietary SVF cell therapy technology that treats and relieves symptoms of inflammation caused by aging, disease and degeneration. Cellular therapies have the potential to treat a vast amount of diseases.

Target markets are Orthopedics, Periodontics and Sports Medicine. SVFC is the only public commercial stem cell company in the U.S. that has the potential to be very profitable.The procedure is done in one day without manipulation of SVF cells and heals a patient with little or no pain and swelling.

IntelliCell ™ is the only company in the United States to meet FDA (Law 361) guidelines for this procedure.

Until now, professional athletes had to go overseas to get similar treatments for sport related injuries. Orthopedic doctors have successfully relieved inflammation and re-grew tissue and bone within days or weeks.
There are numerous advantages to the technology that Dr. Victor has developed. Ultrasonic Cavitation breaks down fat globules and releases the cells that are inside the blood vessel walls using
only sound and water. Treatment uses a person’s own adipose fat stem cells by using Ultrasound Cavitation technology to produce SVF (stromal vascular fraction) cells. The procedure done by
IntelliCell ™ is less expensive, uses less fat, is less time consuming–done within an hour. The procedure is also free from the use of enzymes or chemicals and gentler on cells.

5-10 times more cells can be manufactured from only 2 oz. of fat over comparable methods costing only $3000-10,000 in the U.S. vs. $50,000 over seas.

Regenerative medicine is a rapidly forming trend. SVF cell therapy repairs and regenerates damaged/diseased/aging organs, tissues and cells. IntelliCell™’s technology is an innovation of medical technology. The treatment offers 1000 times more potency in alleviating joint pain and swelling vs. cortisone.

Revenues through licensing fees...

http://www.sec.gov/Archives/edgar/data/1125280/000101376212000880/form10k.htm

In consideration for the grant of the exclusive license, the licensee agreed to pay us an up-front license fee of $1,000,000 payable as follows: (i) an initial installment of One Hundred Fifty Thousand Dollars ($150,000) upon execution of the agreement; (ii) One Hundred Thousand Dollars ($100,000) within three (3) days of the completion of the Lab Equipment (as defined in the agreement) having been delivered and installed (in accordance with applicable cGMP’s and cGTP’s of the US FDA) and the Lab Technician (as defined in the agreement) for the initial Laboratory Facility (as defined in the Thailand Agreement) having completed training; and (iii) the balance of Seven Hundred Fifty Thousand Dollars ($750,000) to be placed in escrow with counsel for the Company upon the payment of the second installment, with such funds to be held in escrow for a period of ninety (90) days, with such funds to be released upon satisfaction by the parties that the Lab Equipment is in working order and the Lab Technician has been adequately trained.

The company's (SVFC) expansion plan is to acquire cash flow positive ambulatory surgery centers in major US markets beginning in 2013 with a target of operating 20 centers by 2016. Each center will generate between $10M to $30M of revenue per annum in traditional surgical procedures such as orthopedics, aesthetic plastic surgery, urology, etc.
IntelliCell will place a cGTP compliant cellular processing laboratory in each surgical facility and offer regenerative medical procedures in addition to the surgical procedures. The company believes an additional $10M to $15M can be generated per annum from the cellular therapies at an average gross profit of 70% from the cellular procedures.
The financial model target is to reach over $600m in combined revenues by 2018

http://proactivecapital.com/wp-content/uploads/2013/02/imtellicellfactsheet.pdf

LETS LOOK AT THE CHARTS...PEAK WAS $4.40...AND ON MARCH ,2012..SVFC WAS @$2.25...NOW REVERSING...

https://www.google.com/finance?chdnp=1&chdd=1&chds=1&chdv=1&chvs=maximized&chdeh=0&chfdeh=0&chdet=1371347018608&chddm=448477&chls=IntervalBasedLine&q=OTCMKTS:SVFC&ntsp=0&ei=Pxi9UeDIB-mp0AHYvAE

TRANSFER AGENT: CONTINENTAL

FLOAT: 27 MILLION

AUTHORIZED SHARES: 500M authorized shares and the outstanding shares after full dilution is upwards of 150M with 39M in warrants.

Anna Rhodes <arhodes@intellicellbiosciences.com>
3:49 PM (4 minutes ago)

to me
Hi xxxx,

Thank you for your interest in IntelliCell BioSciences. The transfer agent for the company is Continental and the float is approximately 27M. There are 500M authorized shares and the outstanding shares after full dilution is upwards of 150M with 39M in warrants.

I hope this information is helpful to you.

Best regards,
Anna

Anna Rhodes
Executive Vice President of Operations
IntelliCell BioSciences, Inc.
460 Park Ave., 17th Floor
New York, NY 10022
T: 646.576.8710
C: 917.209.6636
F: 212.249.1482
E: arhodes@intellicellbiosciences.com
www.intellicellbiosciences.com

Intellicell Biosciences @ISSUU Stem Cell Summit in Houston:

Page 65

This summit was about analysis and market forecasts for 2012-2022

http://issuu.com/rrypublications/docs/scs12_executive_summary?e=3996674/3784571

LETS LOOK AT THE MANAGEMENT...

INTELLICELL BIOSCIENCES CEO STEVEN VICTOR..

Dr. Steven Victor, founder and CEO of IntelliCell has been at the forefront of clinical product and process development for over 20 years. The patent pending process that Dr. Victor has developed for IntelliCell™ has been in research for over 4 years. In addition to developing clinical products that are used nationally and internationally in the medical aesthetics field, Dr. Victor is a practicing dermatologist in New York City. Dr. Victor's interest in regenerative medicine began well over a decade ago with the clinical use of autologous fibroblast cells for the purpose of dermal regeneration. Dr. Victor received his medical degree from New York college and a Bachelor of Arts degree from New York University and has held hospital based teaching positions. He has been a sought after national figure for teaching physicians new clinical techniques worldwide for over 20 years. Dr. Victor has also been featured in national and local media as a clinical subject matter expert in regenerative medicine, medical aesthetics, and dermatology
In addition, teaching appointments to Beth Israel Medical Center ("Beth Israel") and Lenox Hill Hospital ("Lenox Hill") have significantly added to his experience as a teacher and a doctor.

Other rewarding positions include his appointments as the consulting dermatologist for Elizabeth Arden, Clarins, Pierre Cardin, as well as Angio Medical Corporation, Medicis Pharmaceuticals, and the Orentreich Foundation for the Advancement of Science. In addition Dr. Victor has had the opportunity to give numerous newspaper, magazine and television interviews, and is honored to have been named one of New York Magazine's "Best Doctors in New York," Woodward and White's "Best Doctors in America," and Town & Country's "Best Cosmetic Surgeons." He has pioneered, perfected and delivered some of the most ground breaking and highly effective skin rejuvenation treatments that exist today. Beginning in 1982, he helped develop the first true cosmeceutical. In 1988, he introduced the first professional peeling formula to the aesthetician and plastic surgery worlds. In 2001, he formulated a full line of cosmeceutical treatments. Other highlights have included bringing Botox to Paris, and Restylane from Europe to the United States. In 1992 he was featured by the New York Times for bringing Mesotherapy to the United States.

In 2002, his first book, "Ageless Beauty, A Dermatologist's Secrets to Looking Younger Without Surgery" was published. Today his practice continues to grow with both new patients and long-term patients for more than 30 years, many of them in the worlds of modeling, show business and society. These include a number of celebrities and household names.

OneMedRadio: Intellicell BioSciences CEO Talks Stromal Vascular Cells...Intellicell has demonstrated the process is faster (about 30 minutes vs. 2 hours), less expensive, and more efficient than protocols using endotoxins and enzymes...IntelliCell will also be seeking to develop technology licensing agreements with technology developers, universities, and international business entities...Intellicell is now exploring clinical studies in autologous cellular treatments for osteoarthritis, periodontal (gingival gum regeneration), aesthetics (wrinkle market), sports medicine injuries, and multiple sclerosis.

http://www.onemedplace.com/blog/archives/12409

TRANSCRIPT BELOW...

Matthew Margolis: Greetings from OneMedRadio, I’m Matt Margolis. Today, I’m with Dr. Steven Victor, Chairman and CEO of Intellicell BioSciences, a New York City-based regenerative medicine company developing a medical process resulting in the acquisition of stromal vascular fraction cells. These cells are known to contain significant numbers of various cell types and the company is exploring applications in osteoarthritis and sports medicine injuries as well as aesthetics and periodontal. Intellicell trades under the symbol S-V-F-C on the OTC market. Thank you for joining us, Dr. Victor.

Steven Victor: It’s a pleasure to be here, Matt.

MM: So let’s start with these cells and Intellicell’s proprietary technology. What exactly are stromal vascular fraction cells?

SV: Okay. So in the world, there’s about 120 companies who take adipose tissue commonly known as fat and use an enzyme to process the fat to remove what we call the stromal vascular fraction cells that actually sit in the blood vessels in the fat. As a matter of fact, if you look at the body, every single blood vessel in the body have stromal vascular fraction cells and these are the cells that the body releases when you injure yourself to repair your cells.

Intellicell BioSciences, what we did we found a way of removing these cells by a mechanical means called ultrasonic cavitation so we don’t have to use any enzymes and that’s a really important point especially in the FDA in the United States because in the FDA, if you use an enzyme, they consider that maximal manipulation because the enzymes can produce things like endotoxins. But just using high frequency sounds waves, there’s no endotoxins. It’s a mechanical way of removing the stromal vascular fraction from the blood vessels so we meet the minimal manipulation requirements of the FDA, which puts us into the 1271.1 or 361, which makes us exempt so we can actually treat patients today.

MM: Let’s take a step back and talk about the company profile. You know, what is Intellicell BioSciences at the employee level?

SV: So Intellicell BioSciences has what’s called the CGTP FDA approved lab, what we call SOP, standard operating procedures, and we have a quality assurance director, we have lab technicians. So if you came into the flagship office on Park Avenue, you see a very sophisticated, well run laboratory with all the standard flow cytometry, isolation hood, everything is done under a very sterile environment. Because remember these cells are taken out of the fat of a person, they’re given back to another person, the same person for treatment so it’s very important to really run the lab in a very high quality CGTP environment with SOPs for sterility and trackability.

Then we have a director of research because right now under the FDA, we’re doing it as minimal manipulation autologous and homologous so we don’t make any clinical claims. So Intellicell manufactures the stromal vascular cells, return the cells to the physician, and then it’s the physician’s choice with consultation with the patient of how they’re going to be treated. So what our director of clinical research is doing, he’s organized several clinical studies, one for osteoarthritis of the knees, one for gum recession would be so far we’ve grown back in the mouse so you won’t need any more surgery, and we’re looking at the aesthetic market or the wrinkle market. So he’s in the process through IRB, IND, FDA trials of organizing these studies and right now, we’re just waiting for the final IRB approvals to begin these trials. So in the near future, we’ll be able to actually make clinical claims for our cellular population instead of just being homologous.

MM: So for the applications that you’re exploring, why are these areas of unmet medical need?

SV: Well if you look at osteoarthritis of the knee, which is the first one we’re looking at, it’s really an unmet clinical need. There is no really good treatment. If you look at steroids, they temporarily make you feel better but at the same time, they’re actually dissolving the bone. So right now in the world of osteoarthritis of the knee, there’s no really great therapeutic modality from exercise to surgery or even medications. We have found with the stromal vascular fraction, we’ve been able to grow back cartilage, we’ve been able to grow back meniscus tissue, we’ve been able to reduce the inflammation to tremendous differences. We use what we call the WOMAC schedule, which is a way of measuring pain and mobility and we’ve seen about an 85% to 95% improvement in these patients that can last up to two or three years. We’ve also grown back cartilage in knees that were bone on bone on MRI. This is one area where there’s a tremendous need for better therapy and we really believe that the stromal vascular fraction is a way of doing it.

In the world of periodontistry, if you’ve ever had a gum recession, in order to fix that, they’d take flap on the roof of the mouth, they have to then graft it into the gums, which is extremely painful. It has 75% take rate and you don’t get total regrowth of the gums. We’ve done so far 10 patients with the periodontist where he’s injected these cells directly into the gums with no other surgery and he’s been able to grow back 99% of the gums in the mouth. So this is a new way of doing this, which will basically prevent surgery, the healing is easy, healing is fast and you have a much better gum regeneration. In addition, he’s able to grow bone in the jaw so people who have, you know, loose teeth or things like that will be able to inject these cells and basically grow new bones so that people won’t lose teeth.

In the aesthetic world, it’s the wrinkle world. It’s basically a way of doing your wrinkles not only to generate the wrinkles but just give you younger skin. So we’re pretty excited about these three fields that we’re focusing on. We believe that the osteoarthritis world is probably over $10B market, the periodontal world is $6B, and then the aesthetic world is probably about a billion plus.

MM: And so what does your clinical progress look like in these applications?

SV: Well understanding what’s interesting what we had to do because we actually manufacture stromal vascular fraction and give them to physician so these indications have all been treated by physicians with high degree of success. So in osteoarthritis of the knee, there’s been over 75 patients treated with clinical improvement up to 85% to 95% on the WOMAC scale. We’ve grown back cartilage on MRIs and in the periodontal world, we’ve grown back gums in ten patients, we’ve grown back bone in the joint in two patients. In the wrinkle world, we’ve treated over a hundred patients for wrinkles with success.

So what’s interesting about what we’re doing because we get to return the cells to physicians under homologous minimal manipulations, they’re actually using cells on patients. But you know the in pharmaceutical world, a lot of the studies that are done, they look good in a small population. Then the medication goes into the bigger population, double blinded and when you open the final envelope at the end of the day after hundreds of millions of dollars and years of studies, you find that the medication doesn’t work.

In our case, we actually are able to use these cells in the clinical arena by physicians so we actually know that we’re going to get a positive outcome even before we start our clinical studies for indications. So these clinical studies will be double blind. They’ll be under IRB, IND with the FDA so we can’t make clinical claims but we know at the end of the study we’re going to get a positive result, which is so different than the world of drugs and pharmaceuticals.

MM: Let’s shift gears a little bit, let’s talk about your IP position. So do you view it as advantageous and favorable?

SV: Well we were the first company to show that you can take a mechanical way in this case ultrasonic cavitation. Other people have tried to do this and ultrasonic cavitation is normally used to lyse cells or blow up cells. We’re able to figure out five parameters if you follow exactly the recipe or the protocol instead of blowing up the cells, you actually keep the cells viable. We’ve shown this in tissue culture. We’ve marked the cells with CD anti-markers, we have this population of cells and all the mesenchymal stems cells that are identical to anybody processing these cells with enzymes.

However, because we don’t use enzymes, which are very expensive, our procedure is much less expensive. It’s actually ten times less expensive. It’s faster, it only takes 30 minutes versus two hours and we’re able to produce more cells from less fat than the enzymes. Most importantly, as I said earlier, because we don’t have any endotoxins or enzymes involved, we’re not adding anything, we’re just using a mechanical way of separating the cells, we believe that we’re under minimal manipulation with the FDA. So we make more cells, we make them faster, we make them cheaper, and we make them better than the enzyme world.

MM: So let’s talk about your most recent news. On October 4th, the company announced that it had been granted a research tissue banking license by the New York State Department of Health. Why is this significant?

SV: Well what we’ve discovered which we filed a patent for also, right now as we talked about whether the enzyme world or our ultrasonic cavitation where, we’re manufacturing stromal vascular fraction from adipose tissue from living patients or living people. We discovered that we could take cadaveric or nonliving tissue or organ donors, we can take their fat. We can use our technology and our protocol on that fat and we can actually produce stromal vascular fraction cell in the same quantity, the same quality as in living tissue. So we’ve done this in multiple times, we’ve now tested it and with the license, we’ll be able to actually manufacture these cells from nonliving cells and we’ll be able to sell them to researchers around the world. So we can really now see a big advance in the world of stromal vascular fraction because prior to this it was very difficult for researchers to obtain adipose tissue or fat from the liposuction doctors believe it or not. So we think there’s going to be a big skyrocket in research and in advancements and discoveries in the world of stromal vascular fraction for treating all kinds of clinical indications.

MM: And what can we expect from Intellicell BioSciences in the next few months and what business development milestones are you seeking?

SV: Well basically, we’re open. We’re in the process of finishing our ambulatory surgery center, which we open in about 30 days to 60 days. We believe that it will do from 10 to 12 million dollars a year with about 25% to the bottom line. The reason we’re running this business model because the FDA wants us to run the CGPT lab. They want us to basically be able to monitor the clinical experience of the patients. They want us to monitor the market into physicians. By owning the ambulatory surgery centers, we basically meet all the needs of the FDA to regulate these cells. Once we open our facility in New York on Park Avenue, we have plans for acquisitions of other ambulatory surgery centers in the country where we can then put our cellular tissue processing labs and turn that ASC into a cellular center for treatments of again we’re going to focus on the sports world, the osteoarthritis world, the periodontal world, and the aesthetic world. So it’s a way of expanding our model that we can easily expand our model throughout the country.

MM: That was a company snapshot with Dr. Steven Victor of Intellicell BioSciences, a New York City-based regenerative medicine company developing a unique process to acquire stromal vascular fraction cells. Intellicell trades under the S-V-F-C on the OTC market. With OneMedRadio, this is Matt Margolis signing off.

Robert J. Sexauer, Executive Vice President Clinical Development

Mr. Sexauer has been in the medical technology industry since 1979 and has served in a series of executive corporate positions with a specialization in international clinical, corporate and product development. In 2006, he formed InterMark Associates Ltd., a London based consulting organization focused on the regenerative medicine industry. Among projects undertaken included a turn around as CEO of a California based nanotechnology company that resulted in a settlement with the SEC and redirection of the company's business. Also, Mr. Sexauer directed the first ever in human clinical trial utilizing two autologous cell lines for regenerative medicine. Prior to InterMark, he was responsible for the corporate launch of Isolagen Europe, Ltd. Isolagen developed a pioneering regenerative medicine autologous cellular application for the anti-aging and dermal regeneration market.

Mr. Sexauer has worked extensively outside the United States while also directing mergers and acquisitions at the corporate level and has been a featured guest lecturer at DePaul University in the graduate school of International Marketing. He has also been a featured speaker at national conferences in the medical and information technology sectors addressing market conditions and valuations for mergers and acquisitions.

Anna Rhodes, Executive VP Operations,INTELLICELL BIOSCIENCES..

Anna Rhodes, our Executive Vice President of Operations, has been actively involved in the cosmetic and cosmeceuticals industries for over 9 years. From 2001 through 2009, Ms. Rhodes held various executive sales positions with Victor Cosmeceuticals, Inc. and Victor Products Inc., with primary responsibility for the development of many of the marketing and collateral materials, formulations and training materials for new product launches as well as managing international distribution. Prior to 2001, Ms. Rhodes held various sales positions in the high fashion industry with companies including Calvin Klein, Agnona and Michael Kors. She was a Magnum Cum Laude graduate of the University of Texas with a Bachelor of Science degree in Business Administration.
Sarah R. Young, Quality Assurance Manager…….INTELLICELL BIOSCIENCES…

Prior to joing IntelliCell Ms. Young managed the QA departments for RTI Biologics, Inc. and Southeast Tissue Alliance, Inc. She is an experienced QA Director with nine years of experience working in high-volume manufacturing settings of human cellular and tissue-based products (HCT/Ps) and medical device products regulated under stringent good manufacturing practices (cGTPs/cGMPs) by the US Food and Drug Administration (FDA) as well as state specific statutes/regulations. She has held a Certified Tissue Bank Specialist certification from the tissue banking industry's quality standards setting organization, the American Association of Tissue Banks (AATB), since 2001, where she has also been a member of AATB's Quality Assurance Committee helping establish quality standards, guidances and providing training to the industry since 2005. She has experience with building new quality programs for partner agencies/satellite offices and training staff, writing standard operating procedures, engineering/designing validation protocols (R&D product development, processing, sterilization/decontamination, labeling, implementing effective corrective and preventive action systems, managing complaints and recalls, auditing and site inspections/qualifications, medical records management and healthcare experience, as well as prior experience with FDA.

LETS TAKE A LOOK AT THE HOT BLUE CHIP LUMINARIES ON THE BOARD OF DIRECTORS..

Leonard L. Mazur

COO Triax, Interim COO of IntelliCell BioSciences

Mr. Leonard L. Mazur Co-founded Triax Pharmaceuticals, LLC and serves as its Chief Operating Officer. Mr. Mazur also Co-Founded Akrimax Pharmaceuticals in 2007. Mr. Mazur began his pharmaceutical career with Cooper Laboratories in 1971, where he served as a Product Manager for ophthalmology, dermatology and other products. He was responsible for creating and growing the business that was sold to Pierre Fabre, a French dermatology company, in 2002. In 1995, he founded Genesis Pharmaceutical, Inc., and served as its Chairman, Chief Executive Officer from 1995 to 2005 and President. In 1989, he became one of the first employees of Medicis Pharmaceuticals, a start-up dermatology pharmaceuticals company. Mr. Mazur was responsible for acquiring brands, as well as sales and marketing. He was promoted to Marketing Manager with responsibility for the ethical OTC division where he managed sales and licensing. In 1984, he joined ICN Pharmaceuticals as Vice President of Marketing and Sales, and managed all aspects of the US pharmaceuticals group, including marketing, sales, licensing, and acquisitions. In 1981, he joined Knoll Pharmaceuticals as Director of Product Management. After a 2-year transition period, Mr. Mazur joined Krivulka in founding Triax. He serves as a Vice Chairman of Akrimax Pharmaceuticals. Llc. He has been a Director of PhotoMedex, Inc. since May, 2009.

Myron Z. Holubiak..joins INTELLCIELL BIOSCIENCES..

President, 1-800-Doctors, Inc.
Mr. Holubiak is also Chairman of the Board of Directors of BioScrip
He co-founded and served as CEO to Emron, Inc (Not to be mixed up with Enron)
Mr. Holubiak also currently serves on the Board of Trustees for the Academy of Managed Care Foundation
Mr. Holubiak is the former President of Roche Laboratories, Inc
Mr. Holubiak was President, Chief Operating Officer and member of the Board of Directors of iPhysicianNet, Inc.
Mr. Holubiak was President and Chief Operating Officer of HealthSTAR Communications, Inc.,
Mr. Holubiak served on the board of directors of Nastech Pharmaceuticals Company, Inc. (now Marina Biotech, Inc.)
Mr. Holubiak is also a member of the board of directors of Venture Biosciences, Inc.

.....Recently joined Intellicell biosciences..Mr. Holubiak served as the President of Roche Laboratories, USA and was responsible for all U.S. operations including oversight of the development and launch of the obesity product Xenical

Mr. Myron Z. Holubiak serves as a Senior Partner of 1-800-Doctors.com Inc. and has been its President since May 2007. Mr. Holubiak serves as a Senior Executive with a broad background in the pharmaceutical industry and healthcare companies. He was a Partner of HealthSTAR Communications Inc., since 2002 and served as its Group President and Chief Operating Officer from November 2003 to April 2007 and also served as its Group President, Field Level Marketing Group from August 2002 to October 2003. Mr. Holubiak is an accomplished biotech and pharmaceutical senior executive with over 30 years of industry experience including directing Roche Laboratories. From August 2001 to June 2002, Mr. Holubiak served as the President and Chief Operating Officer of iPhysician Net Inc. From December 1998 to August 2001, Mr. Holubiak served as the President of Roche Laboratories, USA and was responsible for all U.S. operations including oversight of the development and launch of the obesity product Xenical (R). Previously, he spent 19 years in a variety of marketing, sales and executive positions with Roche Laboratories. Mr. Holubiak co-founded Emron Inc., and served as its Chief Executive Officer. He has been Chairman of the Board at BioScrip Inc. since April 18, 2012. He has been a Director of BioScrip Inc., since March 2005, and of Ventrus Biosciences Inc., since July 2010. He has been Director of IntelliCell BioSciences, Inc since October 2012. He serves as a Director of US Wellness Inc. and 1-800-Doctors.com. Mr. Holubiak served as a Director of Chronimed, LLC (also known as Chronimed Inc.), since October 28, 2002. He served as a Director of iPhysician Net Inc., from August 2001 to June 2002. He served as a Director of MDRNA Inc. (now, Marina Biotech, Inc.) since June 2004. He serves as a Director of the Children of Chernobyl Relief Foundation. Mr. Holubiak was a Trustee of the Robert Wood Johnson Hospital Foundation from 2000 to 2001. He was a Founding Member of the Academy of Managed Care Pharmacy, the professional society of managed care pharmacists. Mr. Holubiak holds a BS in Molecular Biology and Biophysics from the University of Pittsburgh in 1969 and a graduation in Biophysics from the University of Pittsburgh in 1970 and has completed medical training.

Micheal Hershman ..who recently joined the Board of Directors of Intellicell biosciences..For the past 12 years he has been a member of Interpol’s International Group of Experts on Corruption and NOW SERVES AS THE CHAIRMAN and also the FOUNDER of the FAIRFAX GROUP!!...

http://www.fairfaxco.us/bio_hershman.php

Michael Hershman is an internationally recognized expert on matters relating to transparency, accountability, governance, litigation and security. The Fairfax Group, founded in 1983, has been retained by governments, corporations, law firms and international financial institutions to assist on matters relating to the conduct of senior-level officials and/or the entities with which they do business.

Mr. Hershman has been called upon repeatedly to respond in times of crisis by governments, public and private companies, law firms and individuals. In high profile controversies, criminal prosecutions and civil litigation, Fairfax has participated in some of the most prominent disputes around the world for the last twenty-eight years. From high profile events, like the Olympics and Super Bowls, to targeted terrorist attacks, Fairfax has responded to provide assistance to individuals and entities facing serious, wide-spread threats against their persons and property. Fairfax has provided litigation support, state-of-the-art digital forensics and security measures, crisis monitoring and response, and advice to corporate boards and executives and governments in the midst of some of the most contentious situations.

In December 2006, for example, Mr. Hershman was appointed as the independent compliance advisor to the board of directors of Siemens AG, a company with more than 400,000 employees. Similarly, The Fairfax Group has assisted governments from India to Chile on ethics matters, and has served as the appointed monitor of companies that have violated laws, rules or regulations.

Mr. Hershman began his career in intelligence and investigations in Europe during the late 1960s as a special agent with U.S. Military Intelligence, specializing in counter-terrorism. After leaving the military, he moved to investigations of government misconduct and financial fraud for the New York State Attorney General's Office and the Office of the Mayor of New York City.

Later, Mr. Hershman served as a senior staff investigator for the Senate Watergate Committee, and as chief investigator for a joint Presidential and Congressional commission, reviewing state and federal laws on wiretapping and electronic surveillance. After the wiretap commission hearings, Mr. Hershman joined the Federal Election Commission as chief investigator, where he was responsible for audits and investigations of candidates and their campaign committees.

Mr. Hershman then served as deputy staff director for the Subcommittee on International Organizations of the U.S. House of Representatives, which was responsible for legislation and oversight relating to international banks and other U.S. supported international organizations, such as the United Nations.

Immediately prior to founding the Fairfax Group, Mr. Hershman served as deputy auditor general for the Foreign Assistance Program of the U.S. Agency for International Development (AID), where he led investigations and audits of major U.S. funded projects overseas, and was responsible for worldwide security at all foreign AID missions. Mr. Hershman was awarded the Superior Honor Medal for his service at AID.

In 1993, along with Peter Eigen, Mr. Hershman co-founded Transparency International, the largest independent, not-for-profit coalition promoting transparency and accountability in business and in government. For the past 6 years he has served Interpol as a member of the International Group of Experts on Corruption, and for the past 12 years, he has sat on the board of the International Anti-Corruption Conference Committee.

Mr. Hershman is a member of the board of directors of the U.S. Chamber of Commerce Foundation, and advises the Chamber on corporate compliance issues. Since 2007, Mr. Hershman has been a member of the board of directors and the executive committee of the Center for International Private Enterprise.

For the past 12 years he has been a member of Interpol’s International Group of Experts on Corruption and now serves as Vice Chairman. He is also on the board of the International Anti-Corruption Conference Committee. He also serves on the Financial Coalition against Child Pornography, a project of the National Center for Missing and Exploited Children. Additionally, he is a member of the Advisory Council of the George Mason University School of Information Technology and Engineering.

Since 2008, he has been named every consecutive year to the Ethisphere Institute’s list of the top 100 most influential people in business ethics worldwide.

Michael Hershman has given hundreds of speeches throughout the world on issues related to transparency and accountability and has provided commentary on ABC, CBS, NBC, PBS, CNN, CNBC, MSNBC and the Fox News Channel as well as countless national radio shows. For five years he was the co-host of the Public Radio Law Show. He has been quoted and published in the Wall Street Journal, the New York Times, the New York Post, the Washington Post, USA Today, the Financial Times, the National Law Journal and other print media.

Harry Fisch,MD..who joined Intellicell Biosciences...Dr. Harry Fisch is a board certified urologist and is one of the nation's leaders in the diagnosis and treatment of Men's health issues. Internationally renowned, he has pioneered microsurgical techniques for disorders associated with male infertility such as vasectomy reversal and varicocele repair. He has been named to the “Best Doctors in America" and "New York Magazine Top Doctors" the past 9 years. He regularly appears on The Dr. Oz Show as a medical expert on Men's Health and hosts The Harry Fisch Show on Howard 101 which helps men with their most intimate problems and needs.

http://www.harryfisch.com/#sthash.pwfrJrb4.dpuf

http://www.harryfisch.com/

Dr. Arnold I. Caplan...father of the Mesenchymal stem cells..

..Joins Intellicell Biosciences ..Board of Directors..

http://www.biospace.com/News/intellicell-biosciences-announces-dr-arnold-i/263167

DD!!..Mine should not be Your Decision!..Yours should not be My Mistake!..and Vice Versa!.Lets not blame each other!.Happy trading!.

Keep Last Read

Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Volume
Day Range:
Bid Price
Ask Price
Last Trade Time:

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Join the InvestorsHub Community